Akcea Therapeutics News Releases https://ir.akceatx.com/ Akcea Therapeutics News Releases en Akcea and Ionis Announce Upcoming Data Presentations at the 5th European Academy of Neurology Annual Congress https://ir.akceatx.com/news-releases/news-release-details/akcea-and-ionis-announce-upcoming-data-presentations-5th Multiple clinical presentations focus on the long-term clinical benefits of treatment with TEGSEDI® (inotersen) BOSTON and CARLSBAD, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. Wed, 26 Jun 2019 07:00:00 -0400 Akcea Therapeutics News Releases 7726 Akcea and Ionis Announce Upcoming Data Presentations at the 2019 Peripheral Nerve Society Annual Meeting https://ir.akceatx.com/news-releases/news-release-details/akcea-and-ionis-announce-upcoming-data-presentations-2019-0 Multiple clinical presentations focus on the long-term clinical benefits of treatment with TEGSEDI® (inotersen) BOSTON and CARLSBAD, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. Thu, 20 Jun 2019 16:38:00 -0400 Akcea Therapeutics News Releases 7721 Akcea Therapeutics to Present at Upcoming Investor Conferences https://ir.akceatx.com/news-releases/news-release-details/akcea-therapeutics-present-upcoming-investor-conferences-2 BOSTON , May 28, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that management will present a company overview at the Tue, 28 May 2019 07:00:00 -0400 Akcea Therapeutics News Releases 7671 Akcea Reports Financial Results and Highlights for First Quarter 2019 https://ir.akceatx.com/news-releases/news-release-details/akcea-reports-financial-results-and-highlights-first-quarter-0 Achieved First Quarter 2019 TEGSEDI ® (inotersen) Global Net Product Revenues of $7 Million   Novartis exercised its option to license AKCEA-APO(a)-L Rx Received marketing authorization for WAYLIVRA ® (volanesorsen) in E.U. Conference Call Webcast Wednesday, May 8 , 4:30 p.m. Wed, 08 May 2019 16:05:00 -0400 Akcea Therapeutics News Releases 7651 New Long-Term TEGSEDI Safety and Efficacy Data Featured as an Oral Presentation at 2019 American Academy of Neurology Annual Meeting (AAN) https://ir.akceatx.com/news-releases/news-release-details/new-long-term-tegsedi-safety-and-efficacy-data-featured-oral NEURO-TTR phase 3 open-label extension study showed TEGSEDI ® ( inotersen) treatment continued to slow progression over two-year period in patients with Hereditary ATTR amyloidosis with polyneuropathy Ionis Logo Greater efficacy and clinical benefit observed with early initiation of TEGSEDI and no Tue, 07 May 2019 16:05:00 -0400 Akcea Therapeutics News Releases 7646 Akcea and Ionis Announce Approval of WAYLIVRA® (volanesorsen) in the European Union https://ir.akceatx.com/news-releases/news-release-details/akcea-and-ionis-announce-approval-waylivrar-volanesorsen WAYLIVRA is the only therapy for Familial Chylomicronemia Syndrome, or FCS, a devastating, ultra-rare disease BOSTON and CARLSBAD, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. Tue, 07 May 2019 08:41:00 -0400 Akcea Therapeutics News Releases 7641 Akcea Announces Upcoming Data Presentations at the 2019 American Academy of Neurology Meeting (AAN.19) https://ir.akceatx.com/news-releases/news-release-details/akcea-announces-upcoming-data-presentations-2019-american Multiple clinical presentations at AAN focus on the long-term clinical benefits of treatment with TEGSEDI™   (inotersen) An oral presentation of long-term efficacy and safety with 2-year data from the NEURO-TTR open-label study to be presented by Dr. Tom Brannagan BOSTON , May 02, 2019 (GLOBE Thu, 02 May 2019 07:05:00 -0400 Akcea Therapeutics News Releases 7636 Akcea Therapeutics to Hold First Quarter 2019 Financial Results Webcast https://ir.akceatx.com/news-releases/news-release-details/akcea-therapeutics-hold-first-quarter-2019-financial-results Webcast scheduled for Wednesday, May 8th at 4:30 p.m. Eastern Time BOSTON , April 24, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , announced today that it will host a live webcast on Wednesday, May 8 th at 4:30 p.m. Wed, 24 Apr 2019 07:00:00 -0400 Akcea Therapeutics News Releases 7616 Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19) https://ir.akceatx.com/news-releases/news-release-details/akcea-and-ionis-announce-upcoming-data-presentations-2019 Presentations focus on the benefits of treatment with TEGSEDI™ (inotersen) and results show continued efficacy with long-term exposure in the NEURO-TTR open-label extension study BOSTON and CARLSBAD, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. Fri, 15 Mar 2019 16:05:00 -0400 Akcea Therapeutics News Releases 7586 Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRA™ (volanesorsen) https://ir.akceatx.com/news-releases/news-release-details/akcea-and-ionis-receive-positive-eu-chmp-opinion-waylivratm First and only therapy approved for FCS, a serious and rare disease with no approved treatment options BOSTON, Mass. and CARLSBAD, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Fri, 01 Mar 2019 07:45:00 -0500 Akcea Therapeutics News Releases 7571